Ervogastat

Description: Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor. Ervogastat reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH). Target: Transferase. Smiles: O(C1=CC(C=2N=CC(C(N[C@H]3CCOC3)=O)=CN2)=CN=C1)C4=C(OCC)C=CC=N4. References: PFIZER INVESTOR DAY FEATURES SIGNIFICANT NUMBER OF PIPELINE ADVANCES FOR COVID-19 PROGRAMS AND ACROSS NUMEROUS THERAPEUTIC AREAS